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Aim To determine the correlation of urinary fibroblast 
growth factor 23 (FGF23) excretion with blood pressure 
and calcium-phosphorus metabolism.
Methods The study included 42 hypertensive (17 girls) 
and 46 healthy children and adolescents (17 girls) aged 
6-18 years admitted to the Department of Pediatrics and 
Nephrology, Medical University of Białystok between Jan-
uary 2013 and December 2013. FGF23 in urine was mea-
sured using Human Intact FGF-23 ELISA Kit.
Results Hypertensive participants had significantly high-
er urine FGF23/creatinine values than the reference group 
(8.65 vs 5.59 RU/mg creatinine, P = 0.007). Urine FGF23/cre-
atinine positively correlated with systolic blood pressure in 
all participants. In hypertensive patients, urine FGF23/crea-
tinine positively correlated with serum calcium and nega-
tively with serum 25(OH)D, urinary calcium, phosphorus, 
and magnesium.
Conclusion This study found that FGF23 may play an im-
portant role in the pathogenesis of hypertension in chil-
dren and adolescents, but our results should be confirmed 
by further studies.
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Hypertension is a chronic medical condition and a ma-
jor risk factor for cardiovascular disease, heart failure, and 
chronic kidney disease (CKD). Hypertension was found 
to be associated with several factors, among them calci-
um-phosphorus imbalance, lack of vitamin D, and serum 
parathyroid hormone (PTH) (1-5). However, far too little 
attention has been paid to phosphates and hormonal 
mechanisms responsible for their regulation, especially 
since the consumption of phosphorus has considerably 
increased in recent years. Some studies have shown that 
serum phosphorus increases BP (6,7). However, recent 
studies have found that high phosphorus intake reduces 
BP, when the diet is rich in calcium (8-10), while other have 
shown that BP was reduced by low phosphorus and high 
calcium diet (11,12).
Phosphate concentration is primarily regulated by PTH 
and fibroblast growth factor 23 (FGF 23) – phosphatonin, 
produced by osteoblasts/osteocytes in the bone, which, 
similarly to PTH, stimulates phosphaturia. FGF23 decreas-
es renal calcitriol production and inhibits PTH secretion. 
Its main function is to maintain phosphate homeostasis 
by increasing urinary phosphate excretion and decreas-
ing serum 1,25(OH)2D (13,14) In patients with CKD, it pos-
itively correlated with PTH secretion (15,16). The increase 
in FGF23 in those patients led to an early development 
of secondary hypertension by suppression of 1,25(OH)2D 
production (17), and low phosphate intake of phosphorus 
binders caused 35% decrease in plasma FGF23 level (18). 
However in healthy individuals no changes in FGF23 lev-
els were observed after both phosphate deprivation and 
loading (19,20).
FGF 23 is also involved in renal sodium handling (21) and, 
what is even more interesting, it suppresses the expres-
sion of angiotensin-converting enzyme-2 (ACE2) in CKD-
mice and thereby activates renin-angiotensin-aldosterone 
system (RAAS) (22). FGF23 can also influence the RAAS in-
directly through vitamin D (23), which probably reduces 
renin gene expression and secretory activity of the juxta-
glomerular apparatus, the main place of production of 
renin (24).
The investigation of the effect of FGF23 on hypertension is 
not confined to in vitro models. Hypertensive people were 
found to have significantly higher plasma FGF23 level than 
normotensive people (25). FGF23 was shown to have an 
association with markers of inflammation in individuals 
with CKD stages 2-4 (26), and with impaired endothelium-
dependent vasodilatation in healthy individuals and early 
CKD patients (27). This effect of FGF23 might also result in-
directly from a decrease in 1,25 (OH)2D (28). FGF23 also cor-
related with asymmetrical dimethylarginin (ADMA), which 
is an endogenous inhibitor of NO synthase and a biomark-
er of endothelial dysfunction (29).
So far, however, the relevance of FGF23 in primary arte-
rial hypertension has been under-investigated. What is 
more, available data focus on adult hypertensive patients 
and possible relation of phosphorus intake and increased 
FGF23 concentration to elevated BP (25). There is a paucity 
of similar data in children and adolescents. The aims of this 
research were to determine whether urinary excretion of 
FGF23 in hypertensive children and adolescents was high-
er than in healthy controls and whether its urinary level 
correlated with serum calcium, phosphorus, vitamin D, and 
PTH concentrations. Reference group data were obtained 
from the OLAF study, which established the reference 
blood pressure range for Polish children and adolescents. 
A strong correlation between serum and urine FGF23 was 
previously confirmed (r = 0.92, P < 0.001) (30).
PAtientS And MethodS
This cohort study included all 42 hypertensive children and 
adolescents (17 girls and 25 boys) aged 6-18 years who 
were admitted to the Department of Pediatrics and Neph-
rology, Medical University of Białystok between January 
and December 2013. They were referred to our Unit after 
they had been found to have elevated causal BP by their 
GPs. The reference group consisted of 46 healthy children 
and adolescents (17 girls and 29 boys) aged 6-18 years from 
the OLAF study (n = 40) or children of health professionals 
from our Unit (n = 6). The data collection in OLAF study was 
performed between January and November 2009.
Inclusion criteria were age 6-18 years, primary arterial hy-
pertension (confirmed by ambulatory blood pressure 
monitoring [ABPM]–mean systolic or diastolic daytime or 
night-time BP higher than or equal to the 95th percentile 
for age, sex, and height and load systolic or diastolic blood 
pressure higher than 25%) (31), normal clinical examina-
tion, creatinine, and thyroid-stimulating hormone (TSH) 
levels, no abnormalities in urinalysis, and normal renal ul-
trasound and electrocardiogram.
Exclusion criteria were heart failure, renal dysfunction, 
secondary forms of hypertension, diseases of thyroid, 
parathyroid, or adrenal glands, rickets, systemic inflam-
matory conditions, autoimmune and hematological 
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diseases, treatment with contraceptive pills, and treatment 
with vitamin D or calcium. Reference participants did not 
have a family history of hypertension and other CVDs, renal 
disease, diabetes, or urolithiasis. The participants’ medical 
history was taken from their parents.
The study protocol was approved by the Local Committee 
of Bioethics, Medical University of Bialystok, while the OLAF 
study was approved by The Children’s Memorial Health 
Institute Ethics Committee and was performed in accor-
dance with the Declaration of Helsinki.
Body weight and height were measured using a balance 
beam scale and pediatric wall-mounted stadiometer and 
body mass index (BMI) was calculated as weight (in kilo-
grams) divided by the square of height (meters squared). 
Age- and height-specific reference values for BMI were 
generated by the Lambda-Mu-Sigma (LMS) method (32), 
with LMS values taken from the OLAF study (33). Waist cir-
cumference was measured midway between the top of 
the hip bone and the bottom of ribs, and hip circumfer-
ence at the widest portion of the buttocks. The waist-to-
hip ratio (WHR) was calculated by dividing waist circum-
ference by hip circumference. BP was measured using an 
automatic manometer in a sitting position. 3 measure-
ments were obtained in 3-minute intervals and the aver-
age of the second and third measurement was calculated. 
Standard deviation score of systolic and diastolic BP (SDS) 
was used for statistical analysis. Anthropometric methods 
have been described thoroughly in OLAF study (34).
In hypertensive participants, serum creatinine, calcium, 
phosphorus, 25(OH)D, and PTH were measured in blood 
samples taken after 12 hours of overnight fasting. For the 
reference group, these values were taken from the OLAF 
study.
First morning void urine samples were obtained and fro-
zen at-70°C until assaying. Concentration of FGF23 and 
creatinine was assessed and daily urine excretion of cal-
cium, phosphorus, magnesium, sodium, and creatinine 
was also estimated. Urine FGF23 concentration was mea-
sured using a commercially available enzyme-linked im-
munosorbent assay (ELISA) kit, Human Intact FGF-23ELISA 
Kit (Immutopics Inc., San Clemente, CA, USA), according 
to the manufacturer’s instructions. In brief, two polyclonal 
antibodies specific for FGF23 were used to detect amino-
terminal and the carboxyl-terminal portions of FGF23. 
The antibody detecting NH2-terminal parts of FGF23 
were conjugated to horseradish peroxidase and fol-
lowed by color-forming peroxidase substrate containing 
tetramethylbenzidine. The color was measured at 450 nm 
by a microtiter plate reader and compared with a stan-
dard curve. Urinary FGF23 levels were expressed in relative 
units per milliliter (RU/mL).
FGF23 measurements were normalized using urine crea-
tinine concentration to account for the influence of uri-
nary dilution. Urine creatinine levels were determined by 
up-dated Jaffé’s method (35). FGF23 levels were expressed 
as urine FGF23 to creatinine ratio (FGF23/cr.) in RUs per 
milligram creatinine (RU/mg cr.). Urine calcium, phospho-
rus, and magnesium levels were determined with a Co-
bas-Integra 800 analyzer and Roche reagents (Roche, In-
dianapolis, IN, USA). Serum creatinine was determined by 
Jaffe reaction and PTH using Immulite 2000 Intact PTH as-
say (Siemens, Deerfield, IL, USA). The estimated glomeru-
lar filtration rate (eGFR) was calculated from the updat-
ed Schwartz formula: eGFR = 0.413 × G (cm)/Lcr (mg/dL), 
where G is growth and Lcr is serum creatinine level.
ABPM was performed using the oscillometric monitor 
(Spacelabs Healthcare, Snoqualmie, WA, USA). The moni-
tors were programmed to measure BP every 15 minutes 
during daytime (8:00-22:00) and every 30 minutes during 
night-time (22:00-8:00), corrected according to the par-
ticipants’ diaries if necessary. Recording started between 8 
and 9 am and lasted for 24 hours. Recordings with a mini-
mum of 80% of measurement and without breaks longer 
than 2 hours were used. Mean systolic (sBP) and diastol-
ic blood pressure (dBP) were calculated separately for the 
24-h period, awake period, and sleeping period. We also 
measured load systolic (LSBP) and diastolic blood pressure 
(LDBP) during the day and night. Hypertension on the ba-
sis of ABPM was defined as mean daytime or night-time 
LSBP or LDBP levels ≥95th percentile and daytime or night-
time LSBP or LDBP levels higher than 25%. The values were 
adjusted by sex and body height according to the refer-
ence values (33). Participants or their parents were asked 
to record the bedtime and waking-up time. After 24 hours, 
the data downloaded using the manufacturer’s software.
Statistical methods
Data were analyzed using STATISTICA (StatSoft, Inc., Tulsa, 
OK, USA), version 10. Categorical variables are expressed as 
counts (percentage) and continuous variables as median 
and interquartile range, unless stated otherwise. The Sha-
piro-Wilk test was used to test the normality of distribution. 
The groups were compared with χ2 test and Fisher exact 
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test for categorical variables and t test for continuous vari-
ables if normally distributed or Mann-Whitney test if not 
normally distributed. Correlations between FGF23/cr. and 
other variables were evaluated by Pearson or Spearman’s 
test (ρ) as appropriate. P < 0.05 was considered statistically 
significant.
ReSultS
Hypertensive participants had significantly higher weight, 
BMI, standard deviation score of BMI specified by the use 
of LMS algorithm (BMI SDS), waist and hip circumference, 
and WHR. They also had significantly higher average of 
systolic and diastolic BP, sBP SDS and dBP SDS, and urine 
FGF23/cr. (P < 0.001, P < 0.001, P = 0.007, respectively) (Ta-
ble 1) (Figure 1).
We found no significant differences in urine FGF23/cr. ex-
cretion between boys and girls. We analyzed the correla-
tions between urine FGF23/cr. and parameters of physical 
development and BP in all participants and the correla-
tions between FGF23/cr. and biochemical parameters and 







Sex (M/F)  25/17  29/17 0.828
Age (years)  17 (16-17)  16 (15-17) 0.730
Height (cm) 163 (143-174) 161.8 (137.1-172) 0.760
Weight (kg)  61.65 (49-80)  52.8 (32-61) 0.005
Body mass index standard deviation score   1.79 (0.74-2.14)   0.19 (-0.21-1.03) ≤0.001
Waist to hip ratio   0.89 (0.81-0.92)   0.82 (0.76-0.84) ≤0.001
Systolic blood pressure standard deviation score   1.5 (0.85-2.17)   0.33 (-0.2-0.72) ≤0.001
Diastolic blood pressure standard deviation score   1.17 (0.82-2.1)   0.43 (0.02-0.9) ≤0.001
Creatinine (mg/dL)   0.58 (0.45-0.74) - -
Calcium (mmol/L)   2.55 (2.5-2.6) - -
Phosphorus (mg/dL)   4.36 (3.93-5.02) - -
25(OH)D (ng/mL)  19 (12-23) - -
Parathyroid hormone(pg/mL)  24.6 (18.7-38.5) - -
Glomerular filtration raterate(mL/min/L,73m2) 111.1 (95.6-131.64) - -
Urinary excretion of calcium (mg/kg/24 h)   1.6 (1.13-2.48) - -
Urinary excretion of phosphorus (mg/kg/24 h)  11.72 (9.49-14.97) - -
Urinary excretion of magnesium (mg/dL)   1.29 (0.95-1.64) - -
Urine creatinine (mg/dL)  91.08 (61.98-130.35) 122.64 (87.81-145.49) 0.029
Urine fibroblast growth factor23/creatinine (RU/mg) creatinine)   8.65 (5.19-12.6)   5.59 (4.4-7.71) 0.007
*Values are presented as median and interquartile range.
tAble 2. Correlations between urine FGF23/creatinine and parameters of physical development, serum concentration of calcium, 
phosphorus, 25(oh)d, parathyroid hormone, and urinary excretion of calcium, phosphorus and magnesium in hypertensive and 
reference group
Correlation coefficient (ρ) P
Age (years) 0.102 0.348
Body mass index standard deviation score(kg/m2) 0.231 0.035
Systolic blood pressure standard deviation 0.281 0.022
Diastolic blood pressure standard deviation 0.191 0.099
Serum calcium (mmol/L) 0.361 0.014
Serum phosphorus (mg/dL) 0.154 0.339
Serum 25(OH)D (ng/mL) -0.322 0.036
Serum parathyroid hormone (pg/mL) 0.034 0.828
Glomerular filtration rate mL/min/1.73m2 0.093 0.553
Urinary excretion of calcium (mg/dL) -0.572 ≤0.001
Urinary excretion of phosphorus (mg/dL) -0.711 ≤0.001
Urinary excretion of magnesium (mg/dL) -0.82 ≤0.001
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urine electrolyte excretion in hypertensive participants. 
Significant positive correlations were found between urine 
FGF23/cr. and BMI SDS (ρ = 0.231, P = 0.035) and sBP SDS 
(ρ = 0.281, P = 0.022) in all participants. However, the cor-
relation between FGF23 and BMI SDS may be a result of 
higher BMI values in hypertensive children than in the ref-
erence group. We observed no significant correlation be-
tween FGF23/cr. and dBP or dBP SDS (Figure 2), but we ob-
served a significant positive correlation between FGF23/cr. 
and serum calcium concentration (ρ = 0.361 and P = 0.013).
We also observed a significant negative correlation of urine 
FGF23/cr. with serum 25(OH)D level (ρ = -0.322, P = 0.036) 
and with urinary calcium, phosphorus, and magnesium 
excretion (respectively, ρ = -0.572, ρ = -0.711, ρ = -0.822; 
P < 0.001) (Table 2).
The factors that significantly correlated with urine FGF23/
cr. ratio in single regression analyses were included into 
multiple regression and created two models. In the first 
one, three parameters (BMI- Z-score, SBP SDS, and urine 
calcium excretion) accounted for 32% of the variations in 
FGF23/cr. ratio level (ρ = 0.568, P = 0.064) and only calcium 
excretion was significant (P < 0.001). In the second mod-
el, four parameters (SBP SDS, serum vitamin D3, and urine 
calcium and phosphorus excretion) accounted for 30% of 
the variations in FGF23/cr. ratio level (ρ =  = 0.551, P = 0.131) 
and only calcium excretion was significant (P < 0.001).
diSCuSSion
The most interesting finding of this study was significantly 
higher concentration of urine FGF23in hypertensive par-
ticipants than in the reference group and the positive cor-
relation of FGF23 with systolic BP but not diastolic BP. The 
latter observation may be related to the fact that the ma-
jority of children and adolescents in our study had isolat-
ed systolic hypertension. Our observation of higher FGF23 
levels in hypertensive patients is consistent with previous 
research on adult population (25). This fact may have some 
clinical implications. FGF23 might become a target for new 
antihypertensive drugs, but it needs to be confirmed by 
further studies, especially on the relation of serum FGF23 
and blood pressure regulation.
We found a negative correlation between FGF23 and uri-
nary phosphorus excretion. Other studies found positive 
correlation between FGF23 and phosphaturia but mainly 
in CKD patients (13,18), while our study included individu-
als with a normal GFR. Circulating FGF23 concentration in-
creases with declining renal function in patients with CKD, 
but does not change in response to variation in phosphate 
intake in healthy participants. What is more, to assess urine 
FGF23 concentration, we used an assay detecting a full-
length human FGF23, which is better than C-terminal as-
say that also detects accumulated fragments (36).
Our study found that FGF23 played an important role in 
the pathogenesis of hypertension in young population. 
However, we have to take into consideration some study 
limitations, such as small sample, single-center design, 
and lack of some biochemical findings like serum crea-
tinine, calcium, phosphorus, PTH, or urinary excretion of 
calcium phosphorus, magnesium in the reference group. 
FiGuRe 1. urine fibroblast growth factor23/creatinine (FGF23/
cr) in hypertensive (ht) and reference group (R).
FiGuRe 2. Correlation between FGF23/creatinine and systolic 
(ρ = 0.281, P = 0.022) and diastolic blood pressure (ρ = 0.191, 
P = 0.099) (sbP – blue line, dbP – red line).
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Therefore, our results have to be confirmed by further re-
search in the following areas: 1. measurement of serum 
FGF23 in hypertensive children and adolescents; 2. assess-
ment of the possible relationship between FGF23 and ac-
tivation of RAAS; and 3. assessment of the correlation be-
tween FGF23 and reactive oxygen species production and 
nitric oxidesynthesis.
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